Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Als symbols : Reta save search
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs
Published: 2022-02-28 (Crawled : 12:30) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -11.98%
H: 43.04%
C: 42.35%
als financial results ces program results
Reata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on Development Programs on February 28, 2022
Published: 2022-02-18 (Crawled : 12:30) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.99%
H: 3.66%
C: -0.69%
als financial results program report results
Reata Pharmaceuticals 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Reata Pharmaceuticals, Inc. - RETA
Published: 2022-02-18 (Crawled : 03:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.99%
H: 3.66%
C: -0.69%
als ces 100 deadline
REATA PHARMACEUTICALS 72 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuits Against Reata Pharmaceuticals, Inc. - RETA
Published: 2022-02-16 (Crawled : 04:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -2.24%
H: 4.36%
C: 3.63%
als ces 100 deadline
REATA PHARMACEUTICALS, INC. (NASDAQ: RETA) SHAREHOLDER CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
Published: 2022-02-04 (Crawled : 14:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.08%
H: 2.45%
C: -0.41%
als nasdaq deadline
Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 1.0%
H: 13.68%
C: 11.81%
new drug treatment fda als application drug one submission friedreich's ataxia friedreich’s ataxia
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Reata Pharmaceuticals, Inc. (RETA) Investors
Published: 2022-01-21 (Crawled : 17:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -2.6%
H: 3.31%
C: -1.39%
als ces
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Reata Pharmaceuticals, Inc. - RETA
Published: 2022-01-14 (Crawled : 05:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.17%
H: 3.88%
C: 3.38%
als ces deadline
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Reata Pharmaceuticals, Inc. - RETA
Published: 2021-12-31 (Crawled : 05:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.83%
H: 5.47%
C: 0.8%
als deadline
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.